Physician profile
Rohit Bhatheja
NPI 1912097627
$257,287.73
in general payments reported to CMS, 2019-2025
35 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45K · 2020: $4,611 · 2021: $4,025 · 2022: $23K · 2023: $49K · 2024: $102K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $127K · Consulting Fee: $20K · Travel and Lodging: $13K · Food and Beverage: $11K · Honoraria: $8,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $127,142.55 |
| Consulting Fee | $20,305.00 |
| Travel and Lodging | $13,447.81 |
| Food and Beverage | $11,126.95 |
| Honoraria | $8,645.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $57,437.73 | 2022-2025 | Jardiance |
| Penumbra, INC. | $36,296.88 | 2019-2025 | Indigo System, Penumbra System |
| Abbott Laboratories | $34,994.18 | 2019-2025 | Diamondback Coronary, Dragonfly Opstar, Optis |
| Chiesi USA, INC. | $27,360.57 | 2023-2025 | Kengreal |
| Cardiovascular Systems INC. | $25,401.90 | 2019-2023 | Diamondback Coronary |
| Boston Scientific Corporation | $18,440.57 | 2019-2025 | General - Vascular Access, General - Balloon Catheters, Watchman Access System |
| Amgen INC. | $17,103.14 | 2022-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $9,454.65 | 2022-2025 | |
| Philips North America LLC | $9,239.40 | 2019-2023 | |
| Ekos Corporation | $7,500.00 | 2019 | |
| Lilly USA, LLC | $6,484.33 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Terumo Medical Corporation | $2,885.85 | 2024 | Surflash, Tr Band, Glidesheath Slender |
| Medtronic, INC. | $1,998.07 | 2021-2024 | |
| Shockwave Medical, INC | $431.10 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $420.51 | 2023-2025 | Impella |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $402.86 | 2022-2025 | Barostim Neo System |
| Siemens Medical Solutions USA, INC. | $175.00 | 2019 | |
| Merck Sharp & Dohme LLC | $171.00 | 2022-2025 | Verquvo |
| Novo Nordisk INC | $165.65 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Edwards Lifesciences Corporation | $144.68 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $121.68 | 2025 | Eliquis, Camzyos |
| Biotronik INC. | $89.75 | 2019 | |
| Esperion Therapeutics, INC. | $81.09 | 2025 | Nexletol |
| Livanova USA, INC. | $80.17 | 2019 | |
| Pfizer INC. | $61.69 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $56.78 | 2024-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $49.53 | 2025 | |
| Myocardial Solutions, INC. | $47.50 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $46.44 | 2025 | Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $42.68 | 2023-2025 | Lifevest |
| Stryker Corporation | $31.51 | 2025 | Flowtriever |
| Kestra Medical Technology Services, INC. | $28.72 | 2025 | Assure Wcd |
| Angiodynamics, INC. | $26.98 | 2025 | Venacure 1470 Pro |
| Alnylam Pharmaceuticals INC. | $15.14 | 2025 | Amvuttra |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Bhatheja listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.